Charles S. Berkman

2014 - Ligand Pharmaceuticals

In 2014, Charles S. Berkman earned a total compensation of $1.6M as Vice President and General Counsel at Ligand Pharmaceuticals, a 112% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$115,711
Option Awards$958,516
Salary$288,938
Stock Awards$186,050
Other$5,700
Total$1,554,915

Berkman received $958.5K in option awards, accounting for 62% of the total pay in 2014.

Berkman also received $115.7K in non-equity incentive plan, $288.9K in salary, $186.1K in stock awards and $5.7K in other compensation.

Rankings

In 2014, Charles S. Berkman's compensation ranked 5,585th out of 13,032 executives tracked by ExecPay. In other words, Berkman earned more than 57.1% of executives.

ClassificationRankingPercentile
All
5,585
out of 13,032
57th
Division
Manufacturing
1,998
out of 4,965
60th
Major group
Chemicals And Allied Products
678
out of 1,690
60th
Industry group
Drugs
526
out of 1,369
62nd
Industry
Pharmaceutical Preparations
408
out of 1,042
61st
Source: SEC filing on April 14, 2017.

Berkman's colleagues

We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2014.

2014

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2014

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2014

Nishan de Silva

Ligand Pharmaceuticals

Chief Financial Officer

2014

John Sharp

Ligand Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like